GÖTTINGEN, Germany,
Feb. 17, 2022 /PRNewswire/ -- The
life science group Sartorius today has presented its 2021 Annual
Report. Besides providing detailed information on its business
performance, as well as on innovations, acquisitions and
sustainability initiatives, the company also confirms its
preliminary figures for fiscal 2021, which had already been
published on January 27, 2022.
The company's outlook for fiscal 2022, updated on
February 8, was also confirmed. Accordingly, Group sales
revenue is expected to increase by about 15 percent to 19 percent.
This includes an expected non-organic growth contribution from
acquisitions of about 2 percentage points. The company's underlying
EBITDA margin is forecasted to reach about 34 percent. All figures
for the forecast are based on constant currencies.
Key performance indicators for the full year of 2021
|
Sartorius
Group
|
|
|
Bioprocess Solutions
|
|
Lab Products
& Services
|
|
|
In millions of.
€,
unless otherwise
specified
|
2021
|
20201
|
Δ in %
Reported
|
Δ in %
cc2
|
2021
|
20201
|
Δ in %
Reported
|
Δ in %
cc2
|
2021
|
20201
|
Δ in %
Reported
|
Δ in %
cc2
|
|
Sales Revenue and
Order Intake
|
|
Order
intake
|
4,267.9
|
2,836.3
|
50.5
|
52.3
|
3,483.5
|
2,238.1
|
55.6
|
57.6
|
784.4
|
598.2
|
31.1
|
32.6
|
|
Sales
revenue
|
3,449.2
|
2,335.7
|
47.7
|
49.3
|
2,727.0
|
1,782.6
|
53.0
|
54.7
|
722.2
|
553.0
|
30.6
|
32.0
|
|
•
EMEA3
|
1,411.0
|
935.1
|
50.9
|
50.8
|
1,130.5
|
698.5
|
61.9
|
61.8
|
280.5
|
236.6
|
18.6
|
18.3
|
|
•
Americas3
|
1,141.2
|
812.2
|
40.5
|
45.5
|
913.1
|
651.3
|
40.2
|
45.1
|
228.2
|
160.9
|
41.8
|
47.2
|
|
• Asia |
Pacific3
|
897.0
|
588.4
|
52.5
|
52.3
|
683.5
|
432.9
|
57.9
|
57.7
|
213.5
|
155.5
|
37.3
|
37.3
|
|
Earnings
|
|
EBITDA4
|
1,175.0
|
692.2
|
69.7
|
|
986.3
|
575.9
|
71.3
|
|
188.8
|
116.3
|
62.3
|
|
|
|
EBITDA
margin4 in %
|
34.1
|
29.6
|
|
|
36.2
|
32.3
|
|
|
|
26.1
|
21.0
|
|
|
|
|
Relevant net
profit5
|
553.4
|
299.3
|
84.9
|
|
|
Net
profit6
|
318.9
|
210.1
|
51.8
|
|
|
Financial Data per
Share
|
|
|
Earnings per
ordinary
share5 in €
|
8.08
|
4.37
|
85.0
|
|
|
Earnings per
preference
share5 in €
|
8.09
|
4.38
|
84.8
|
|
|
Employees
|
|
|
Total Number as
of
Dec 31
|
13,832
|
10,637
|
|
|
1 The figures for the
reporting period 2020 were restated due to the finalization of the
purchase price allocation for the acquisitions of BIA Separations
and WaterSep BioSeparations.
2 In constant
currencies abbreviated as "cc"
|
|
3 Acc. to the
customer's location
|
|
4 Relevant /
underlying EBITDA: earnings before interest, taxes, depreciation
and amortization and adjusted for extraordinary items
5 After
non-controlling interest, adjusted for extraordinary items and
non-cash amortization, as well as based on the normalized financial
result and the normalized tax rate
6 After
non-controlling interest
|
|
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
Links
Annual report 2021
Current image files
|
Financial
calendar
|
|
|
March 25,
2022
|
Annual Shareholders'
Meeting
|
|
April 20,
2022
|
Publication of
first-quarter figures (January to March 2022)
|
|
July 21,
2022
|
Publication of the
first-half figures (January to June 2022)
|
|
October 19,
2022
|
Publication of
nine-month figures (January to September 2022)
|
A profile of Sartorius
The Sartorius Group is a
leading international partner of life science research and the
biopharmaceutical industry. With innovative laboratory instruments
and consumables, the Group's Lab Products & Services Division
concentrates on serving the needs of laboratories performing
research and quality control at pharma and biopharma companies and
those of academic research institutes. The Bioprocess Solutions
Division with its broad product portfolio focusing on single-use
solutions helps customers to manufacture biotech medications and
vaccines safely and efficiently. The Group has been annually
growing by double digits on average and has been regularly
expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2021, the company earned sales revenue of
some 3.45 billion euros. At the end of 2021, nearly 14,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe.
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
Contact
Petra
Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sartorius-presents-annual-report-for-2021-301484502.html
SOURCE Sartorius AG
